These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24802806)

  • 1. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.
    Ramirez MJ; Lai MK; Tordera RM; Francis PT
    Drugs; 2014 May; 74(7):729-36. PubMed ID: 24802806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Options in Alzheimer´s Disease: The GABA Story.
    Solas M; Puerta E; Ramirez MJ
    Curr Pharm Des; 2015; 21(34):4960-71. PubMed ID: 26365140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.
    Upton N; Chuang TT; Hunter AJ; Virley DJ
    Neurotherapeutics; 2008 Jul; 5(3):458-69. PubMed ID: 18625457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into serotonin 5-HT4 receptors : a novel therapeutic target for Alzheimer's disease?
    Maillet M; Robert SJ; Lezoualc'h F
    Curr Alzheimer Res; 2004 May; 1(2):79-85. PubMed ID: 15975071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease.
    Garcia-Alloza M; Hirst WD; Chen CP; Lasheras B; Francis PT; Ramírez MJ
    Neuropsychopharmacology; 2004 Feb; 29(2):410-6. PubMed ID: 14571255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical update on the potential for serotonin 5-HT
    Kucwaj-Brysz K; Baltrukevich H; Czarnota K; Handzlik J
    Bioorg Med Chem Lett; 2021 Oct; 49():128275. PubMed ID: 34311086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research.
    Jankowska A; Wesolowska A; Pawlowski M; Chlon-Rzepa G
    Curr Med Chem; 2018; 25(17):2045-2067. PubMed ID: 28554324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.
    Lai MK; Tsang SW; Alder JT; Keene J; Hope T; Esiri MM; Francis PT; Chen CP
    Psychopharmacology (Berl); 2005 May; 179(3):673-7. PubMed ID: 15551121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease.
    Werner FM; Covenas R
    Curr Pharm Des; 2016; 22(14):2064-71. PubMed ID: 26818863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease and age-related memory decline (preclinical).
    Terry AV; Callahan PM; Hall B; Webster SJ
    Pharmacol Biochem Behav; 2011 Aug; 99(2):190-210. PubMed ID: 21315756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update.
    Khoury R; Grysman N; Gold J; Patel K; Grossberg GT
    Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic system, cognition, and BPSD in Alzheimer's disease.
    Chakraborty S; Lennon JC; Malkaram SA; Zeng Y; Fisher DW; Dong H
    Neurosci Lett; 2019 Jun; 704():36-44. PubMed ID: 30946928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.
    Nirogi R; Mohammed AR; Shinde AK; Bogaraju N; Gagginapalli SR; Ravella SR; Kota L; Bhyrapuneni G; Muddana NR; Benade V; Palacharla RC; Jayarajan P; Subramanian R; Goyal VK
    Eur J Med Chem; 2015 Oct; 103():289-301. PubMed ID: 26363507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of the 5-HT
    de Jong IEM; Mørk A
    Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Alzheimer's disease].
    Bombois S; Lebert F; Vellas B; Pasquier F
    Rev Prat; 2005 Nov; 55(17):1913-9. PubMed ID: 16396232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?
    Martorana A; Esposito Z; Koch G
    CNS Neurosci Ther; 2010 Aug; 16(4):235-45. PubMed ID: 20560995
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.